Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EVTCY NASDAQ:GWPH NASDAQ:ICPT NASDAQ:MRTX NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVTCYEvotec$3.69+5.4%$3.79$14.22▼$26.57$1.22B0.982,407 shs50,143 shsGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/AMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ARAREUltragenyx Pharmaceutical$28.68-2.7%$29.29$25.81▼$59.90$2.76B0.211.31 million shs1.37 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVTCYEvotec+0.86%+0.29%-6.91%-12.72%-1.13%GWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%RAREUltragenyx Pharmaceutical+1.66%-6.41%-0.71%-21.07%-50.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVTCYEvotec$3.69+5.4%$3.79$14.22▼$26.57$1.22B0.982,407 shs50,143 shsGWPHGW Pharmaceuticals$218.96$218.59$87.07▼$219.57$6.86B2.15899,771 shsN/AICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/AMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ARAREUltragenyx Pharmaceutical$28.68-2.7%$29.29$25.81▼$59.90$2.76B0.211.31 million shs1.37 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVTCYEvotec+0.86%+0.29%-6.91%-12.72%-1.13%GWPHGW Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%RAREUltragenyx Pharmaceutical+1.66%-6.41%-0.71%-21.07%-50.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVTCYEvotec 0.00N/AN/AN/AGWPHGW Pharmaceuticals 0.00N/AN/AN/AICPTIntercept Pharmaceuticals 0.00N/AN/AN/AMRTXMirati Therapeutics 0.00N/AN/AN/ARAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50184.17% UpsideCurrent Analyst Ratings BreakdownLatest ICPT, GWPH, EVTCY, RARE, and MRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.008/8/2025RAREUltragenyx PharmaceuticalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$136.00 ➝ $128.008/6/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$112.00 ➝ $105.007/28/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$80.007/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $34.007/14/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$65.00 ➝ $55.007/10/2025RAREUltragenyx PharmaceuticalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$88.00 ➝ $65.006/20/2025RAREUltragenyx PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$64.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVTCYEvotec$572.16M2.13$0.03 per share105.53$2.52 per share1.46GWPHGW Pharmaceuticals$311.33M22.05$0.01 per share18,588.22$23.48 per share9.33ICPTIntercept Pharmaceuticals$285.71M2.78N/AN/A$1.72 per share11.05MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39RAREUltragenyx Pharmaceutical$560.23M4.93N/AN/A$2.76 per share10.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVTCYEvotec$7.14M$0.419.00∞N/A20.85%16.02%7.81%N/AGWPHGW Pharmaceuticals-$9.02M-$0.24N/A608.22N/A-11.05%-7.46%-6.13%N/AICPTIntercept Pharmaceuticals$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/AMRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/ARAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)Latest ICPT, GWPH, EVTCY, RARE, and MRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVTCYEvotecN/AN/AN/AN/AN/AGWPHGW PharmaceuticalsN/AN/AN/AN/AN/AICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVTCYEvotec0.532.572.50GWPHGW Pharmaceuticals0.015.134.31ICPTIntercept Pharmaceuticals3.124.222.52MRTXMirati TherapeuticsN/A7.547.40RAREUltragenyx PharmaceuticalN/A2.452.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVTCYEvotecN/AGWPHGW Pharmaceuticals81.00%ICPTIntercept Pharmaceuticals83.81%MRTXMirati TherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipEVTCYEvotecN/AGWPHGW Pharmaceuticals3.10%ICPTIntercept Pharmaceuticals6.20%MRTXMirati Therapeutics3.26%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableGWPHGW Pharmaceuticals1,16131.35 millionN/AOptionableICPTIntercept Pharmaceuticals34141.83 million39.19 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableICPT, GWPH, EVTCY, RARE, and MRTX HeadlinesRecent News About These CompaniesRep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares1 hour ago | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 17 at 4:30 AM | marketbeat.comIs Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity?September 16 at 9:32 AM | insidermonkey.comGreat Lakes Advisors LLC Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 15 at 3:50 AM | marketbeat.comMillennium Management LLC Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 14 at 3:36 AM | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) EVP Karah Herdman Parschauer Sells 2,450 SharesSeptember 13, 2025 | insidertrades.comHC Wainwright Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)September 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Fred Alger Management LLCSeptember 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comCantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)September 9, 2025 | theglobeandmail.comUltragenyx Reports Positive Phase 3 Gene Therapy ResultsSeptember 9, 2025 | msn.comRARE Reports Positive Long-Term Data From Metabolic Disorder StudySeptember 9, 2025 | zacks.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Alliancebernstein L.P.September 9, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. Reports Positive Phase 3 Results for DTX401 Gene Therapy in Glycogen Storage Disease Type Ia with Significant Reductions in Cornstarch Intake and Improved Glycemic ControlSeptember 8, 2025 | quiverquant.comQUltragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)September 8, 2025 | globenewswire.comParkman Healthcare Partners LLC Has $11.02 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 8, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Cinctive Capital Management LPSeptember 7, 2025 | marketbeat.comCubist Systematic Strategies LLC Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARESeptember 7, 2025 | marketbeat.comEFG Asset Management North America Corp. Lowers Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comCutter Capital Management LP Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Grows Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Amazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025ICPT, GWPH, EVTCY, RARE, and MRTX Company DescriptionsEvotec OTCMKTS:EVTCY$3.69 +0.19 (+5.43%) As of 09/16/2025Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.GW Pharmaceuticals NASDAQ:GWPHGW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.Intercept Pharmaceuticals NASDAQ:ICPTIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Ultragenyx Pharmaceutical NASDAQ:RARE$28.68 -0.80 (-2.71%) Closing price 04:00 PM EasternExtended Trading$28.64 -0.04 (-0.14%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
